CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that the company’s co-founders have published data demonstrating the successful engineering of targeted nanoparticles to cross biological barriers, such as the intestinal barrier, and enter the bloodstream, potentially broadening future therapeutic applications for BIND’s Medicinal Nanoengineering platform.
Help employers find you! Check out all the jobs and post your resume.
